Brazil PCOS Name Change Impacts Millions of Women

A global medical consensus has resulted in the renaming of Polycystic Ovary Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The change, which reflects decades of research and input from over 14,000 survey responses and 56 organizations worldwide, aims to correct a long-standing misunderstanding about the condition that affects an estimated 170 million women globally.

The previous name, “polycystic ovary syndrome,” was often misleading. The structures seen on some ultrasounds are not pathological ovarian cysts but immature follicles, which are a symptom of hormonal dysfunction rather than its cause. By centering the ovaries, the old terminology obscured the condition’s true nature as a multi-system syndrome involving hormones, metabolism, and ovarian function.

This naming confusion had real consequences for diagnosis. A 2025 study found that while population-based data shows PMOS prevalence between 4 and 19.6 percent, health system records capture only 0.2 to 5.2 percent. This diagnostic gap is not evenly distributed. Studies show that Black and African American patients are 69 percent more likely to have a missed diagnosis compared to non-Hispanic White patients.

The new name, PMOS, breaks down into three components. “Polyendocrine” refers to the condition’s involvement of multiple hormone systems, including reproductive hormones, androgens like testosterone, insulin, and neuroendocrine hormones that affect mood and metabolism. “Metabolic” highlights that insulin resistance is a core feature for many women, carrying significant downstream risks. “Ovarian” acknowledges that ovarian dysfunction, including irregular cycles, anovulation, and fertility challenges, remains part of the picture but is now understood as one piece of a larger puzzle.

The metabolic component is significant. A 2025 study describes a bidirectional relationship between insulin resistance and PMOS symptoms such as hyperandrogenism and ovulatory dysfunction. PMOS itself also increases the risk of type 2 diabetes. Research shows PMOS has reproductive, metabolic, and psychological impacts across a patient’s lifespan.

When clinicians heard “PCOS,” they often looked for ovarian cysts and menstrual irregularities. The new terminology “polyendocrine metabolic ovarian syndrome” is expected to widen the diagnostic lens. This matters because many women with PMOS do not fit the narrow “classic” presentation. Some have regular periods, while others present with irregular menstrual cycles but no visible follicles on ultrasound. Symptoms like insulin resistance, elevated androgens, acne, hair changes, or metabolic markers point to the same underlying dysfunction.

Reframing the condition as metabolic and endocrine, instead of simply gynecological, is expected to prompt earlier and more comprehensive screening. A woman presenting with unexplained weight gain, fatigue, and skin changes might now be evaluated for PMOS rather than having her symptoms dismissed or sent to separate specialty visits.

For women already diagnosed with PCOS, the name change validates that the condition is not just about the ovaries. It is a whole-body condition that requires whole-body care, including metabolic screening, cardiovascular risk assessment, and attention to mental health. For those who have suspected something was off but have not gotten answers, the evolving understanding of PMOS may help. Patients are encouraged to ask their healthcare providers about comprehensive hormone and metabolic testing, not just an ultrasound.

The renaming of PCOS to PMOS reflects research showing this condition extends far beyond the ovaries. For millions of women affected worldwide, the new terminology validates the ripple effects of the diagnosis that extend beyond reproductive and gynecological health. The hope is that the new name will lead to earlier diagnosis, more comprehensive care, and better recognition of the metabolic and hormonal factors that shape women’s health.